---
title: "Remus Pharmaceuticals Ltd (REMUS) — Share Price, Financials & Analysis"
symbol: "REMUS"
company: "Remus Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/REMUS"
isin: "INE0O5T01011"
nse_symbol: "REMUS"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 1025.44
generated_at: "2026-09-13T18:45:15.424Z"
---

# Remus Pharmaceuticals Ltd (REMUS)

Canonical page: https://tapetide.com/stocks/REMUS

## Company

- **NSE Symbol:** REMUS
- **ISIN:** INE0O5T01011
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2023-05-29
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** remuspharma.com

## About

Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]

## Latest Price

- **Price:** ₹880
- **Change:** -13.05 (-1.46%)
- **Open:** ₹880.1
- **Day High:** ₹892.95
- **Day Low:** ₹870
- **Previous Close:** ₹893.05
- **Volume:** 5900
- **As Of:** 2026-09-11T10:01:43+00:00

## Key Fundamentals

Observed at 2026-09-11T04:45:23.026539Z.

- **Market Cap:** ₹1025.44 Cr
- **Classification:** SME
- **P/E (reported):** 22.8
- **EPS (reported):** ₹36.55
- **Book Value:** ₹297.86
- **Price to Book:** 3
- **Dividend Yield:** 0.06%
- **ROE:** 13.6%
- **ROCE:** 15.69%
- **Debt to Equity:** 0.08
- **Revenue (yearly):** ₹853.63 Cr
- **Net Income:** ₹45.88 Cr
- **EBITDA:** ₹56.69 Cr
- **52-Week High:** ₹987.5
- **52-Week Low:** ₹580
- **RSI (14):** 53.33

## Tapetide Score

- **Score:** 64 / 100
- **Score date:** 2026-09-04
- **Archetype:** Cheap but Weak
- **What it means:** A low multiple sitting on weak financials. Worth establishing what the market is discounting before treating the low valuation as an opportunity — weak fundamentals often justify it.
- **Pillar profile:** Quality: Weak · Valuation: Cheap · Momentum: Rising
- **Percentile:** 95.6 (of 4473 scored stocks)
- **Confidence:** 86%
- **Data coverage:** 71%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 51.88 | 9% |
| growth | 96.98 | 9% |
| momentum | 71.87 | 12% |
| ownership | 83.86 | 24% |
| quality | 35.83 | 22% |
| valuation | 60.71 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Debtor days have improved from 107 to 59.8 days.

### Weaknesses

- Company has a low return on equity of 13.0% over last 3 years.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | 94.17% | -10.61% | 6.07% |
| ebitda margin growth | -18.64% | -56.76% | — |
| net income growth | 19.48% | 76.46% | — |
| revenue growth | 36.52% | 57.64% | — |
| roce | -47.67% | -47.67% | — |
| roe | -45.38% | 19.25% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 29 | 185 | 273 | 348 | 400 | 453 |
| Expenses | 20 | 165 | 252 | 323 | 373 | 424 |
| Operating Profit | 9 | 20 | 20 | 25 | 27 | 30 |
| OPM % | 32 | 11 | 8 | 7 | 7 | 7 |
| Other Income | 2 | 3 | 3 | 3 | 3 | 4 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 |
| Profit before tax | 10 | 22 | 22 | 25 | 28 | 31 |
| Tax % | 25 | 15 | 16 | 19 | 23 | 21 |
| Net Profit | 6 | 19 | 19 | 21 | 22 | 25 |
| EPS in Rs | 4.87 | 13.16 | 11.87 | 13.57 | 14.85 | 16.54 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Sales | 213 | 620 | 854 |
| Expenses | 184 | 575 | 797 |
| Operating Profit | 29 | 46 | 57 |
| OPM % | 14 | 7 | 7 |
| Other Income | 3 | 5 | 7 |
| Interest | 0 | 1 | 1 |
| Depreciation | 1 | 2 | 3 |
| Profit before tax | 30 | 47 | 59 |
| Tax % | 20 | 19 | 22 |
| Net Profit | 24 | 38 | 46 |
| EPS in Rs | 17.69 | 24.64 | 31.39 |
| Dividend Payout % | 4 | 3 | 2 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Equity Capital | 1 | 6 | 12 |
| Reserves | 156 | 250 | 339 |
| Borrowings | 14 | 23 | 27 |
| Other Liabilities | 161 | 154 | 201 |
| Total Liabilities | 333 | 433 | 579 |
| Fixed Assets | 14 | 16 | 18 |
| CWIP | 0 | 0 | 8 |
| Investments | 105 | 186 | 275 |
| Other Assets | 215 | 231 | 277 |
| Total Assets | 333 | 433 | 579 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Cash from Operating Activity | 4 | 7 | 18 |
| Cash from Investing Activity | -9 | -11 | -15 |
| Cash from Financing Activity | 24 | 6 | 1 |
| Net Cash Flow | 19 | 3 | 5 |
| Free Cash Flow | 3 | 3 | 4 |
| CFO/OP | 35 | 32 | 49 |

### Ratios

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Debtor Days | 198 | 64 | 60 |
| Inventory Days | 96 | 35 | 35 |
| Days Payable | 209 | 49 | 37 |
| Cash Conversion Cycle | 85 | 50 | 58 |
| Working Capital Days | 98 | 54 | 57 |
| ROCE % | — | 20 | 17 |

## Shareholding Pattern

### Quarterly

| Category | Mar 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 92.82% | 69.61% | 70.6% | 70.66% | 70.84% | 70.85% | 70.91% | 70.95% |
| FIIs | 0% | 2.38% | 3.25% | 3% | 3.16% | 4.77% | 5.02% | 5.28% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.83% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 6.44% | 21.15% | 20.54% | 20.9% | 20.49% | 19.18% | 18.78% | 18.5% |
| Others | 0.74% | 6.86% | 5.6% | 5.44% | 5.51% | 5.2% | 5.3% | 4.43% |
| No. of Shareholders | 30 | 856 | 1124 | 1577 | 1753 | 398 | 2032 | 2009 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 7 / 6 / 6

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 892.89 | Sell |
| EMA (10) | 896.32 | Sell |
| SMA (20) | 904.72 | Sell |
| EMA (20) | 886.76 | Sell |
| SMA (50) | 821.56 | Buy |
| EMA (50) | 841.96 | Buy |
| SMA (100) | 781.83 | Buy |
| EMA (100) | 797.86 | Buy |
| SMA (200) | 728.77 | Buy |
| EMA (200) | 784.93 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 50.84 | Neutral |
| MACD (12,26,9) | 18.31 | Sell |
| Stochastic (14,3,3) | 33.17 | Neutral |
| ADX (14) | 15.88 | Neutral |
| Williams %R (14) | -78.79 | Neutral |
| ATR (14) | 35.06 | High Volatility |
| ROC (12) | -1.18 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 45.32 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8 Sep - Published newspaper notice for 11th AGM, FY26 annual report dispatch, and e-voting details on September 8, 2026. | [Copy of Newspaper Publication 8 Sep - Published newspaper notice for 11th AGM, FY26 annual report dispatch, and e-voting details on September 8, 2026.](https://nsearchives.nseindia.com/corporate/REMUS_08092026115839_Intimation_of_Newspaper_signed.pdf) |
| 7 Sep - Remus Pharmaceuticals' 11th AGM is on September 29, 2026; e-voting runs September 25-28. | [Shareholders meeting 7 Sep - Remus Pharmaceuticals' 11th AGM is on September 29, 2026; e-voting runs September 25-28.](https://nsearchives.nseindia.com/corporate/REMUS_07092026205838_Intimationofnoticesigned.pdf) |
| 7 Sep - Record date fixed for final dividend of Rs. 0.50 per share; AGM on September 29, 2026. | [Record Date 7 Sep - Record date fixed for final dividend of Rs. 0.50 per share; AGM on September 29, 2026.](https://nsearchives.nseindia.com/corporate/REMUS_07092026205954_IntimationofRecordDatesigned.pdf) |
| 7 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 7 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.](https://nsearchives.nseindia.com/corporate/REMUS_07072026175410_Disclosureunderreg74_5_signed.pdf) |
| 7 Jul - Remus Pharmaceuticals says Regulation 27(2) corporate governance report filing is not applicable on NSE SME platform. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 7 Jul - Remus Pharmaceuticals says Regulation 27(2) corporate governance report filing is not applicable on NSE SME platform.](https://nsearchives.nseindia.com/corporate/REMUS_07072026174926_DisclosureofNonapplicabiltyofReg272_signed.pdf) |
| 7 Jul - Filed Reconciliation of Share Capital Audit Report for quarter ended June 30, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 7 Jul - Filed Reconciliation of Share Capital Audit Report for quarter ended June 30, 2026.](https://nsearchives.nseindia.com/corporate/REMUS_07072026175747_Disclosureunderreg76.pdf) |
| 7 April 2026 - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 7 April 2026 - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/REMUS_07042026180719_Disclosureunderreg74signed.pdf) |
| 7 April 2026 - Remus Pharmaceuticals հայտնում non-applicability of Regulation 27(2) corporate governance reporting on SME Emerge platform. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 7 April 2026 - Remus Pharmaceuticals հայտնում non-applicability of Regulation 27(2) corporate governance reporting on SME Emerge platform.](https://nsearchives.nseindia.com/corporate/REMUS_07042026180349_DisclosureofNonapplicabiltyofReg272signed.pdf) |
| 7 April 2026 - Filed Regulation 76 share capital reconciliation audit report for quarter ended March 31, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 7 April 2026 - Filed Regulation 76 share capital reconciliation audit report for quarter ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/REMUS_07042026181803_Disclosureunderreg76signed.pdf) |
| 6 Sep - Newspaper clippings submitted for postal ballot notice dispatch completion and e-voting information on September 6, 2026. | [Copy of Newspaper Publication 6 Sep - Newspaper clippings submitted for postal ballot notice dispatch completion and e-voting information on September 6, 2026.](https://nsearchives.nseindia.com/corporate/REMUS_06092026114650_IntimationofNewspaperAdvtsigned.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_31793_REMUS_2025_2026_A_13356159_07092026205551.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28236_REMUS_2024_2025_A_5344024_02092025221353.pdf) |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_25299_REMUS_2023_2024_29082024193536.pdf) |
| from nse | [Annual Report 2023 from nse](https://archives.nseindia.com/annual_reports/SME_AR_23162_REMUS_2022_2023_31082023200502_08312023210001.zip) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://nsearchives.nseindia.com/corporate/REMUS_15112025154123_IntimationofTranscriptofConcallsigned.pdf) |
| May 2025 | [Concall - May 2025](https://nsearchives.nseindia.com/corporate/REMUS_23052025191133_Intimationoftranscriptsigned.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://nsearchives.nseindia.com/corporate/REMUS_20082025114358_IntimationunderReg30_InvestorPresentationAug2025.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:45:15.424Z.